Diagnosing HFpEF: What Every Cardiologist Needs to Know

Slides:

Advertisements

Similar presentations

Jim Hoehns, Pharm.D.. ClassificationEF (%)Description HF with reduced EF (HFrEF) ≤40 “systolic HF”; RCTs have mainly enrolled these HF patients; only.

Advertisements

Heart Failure: From Failure to Success

Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.

Multimodal Management of Opioid-Induced Constipation

Hypophosphatasia Understanding the Disease and Improving Diagnosis

The Puzzle of Heart Failure With Preserved Ejection Fraction

Windhi Dwijanarko RSU DADI KELUARGA, PURWOKERTO

Carmarthenshire LHB and Hywel Dda Trust

Program Overview. Primary Care Approaches to Cognitive Dysfunction in Major Depressive Disorder.

Primary Care Challenges in Depression - To Treat or Refer?

Cardiogenic Shock.

The Clinical Enigma of Cardiogenic Shock

Setting the Stage – PAH Therapy Trials Current PAH Pharmacotherapies.

Heart Rate, HF Admissions, and Readmissions

A New Era for NOACs:.

New Challenges Facing Multiple Sclerosis Nurses

Understanding the Many Faces of Pseudobulbar Affect

Protecting Patients With Varicose Veins

Epidemiology Venous Pathophysiology Etiology.

Biomarkers in Heart Failure

Stepping Up Asthma Control for Effective Management

Select Topics in Cardiovascular Medicine

Case Challenges in Chronic Migraine

New Treatments for CTEPH

Addressing Iron Deficiency in Chronic HF

Diagnosis and Management of Narcolepsy in Psychiatry:

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

The Mood Disorder Spectrum

The Chemical Differences Between EPA and DHA.

Treating HFrEF: Challenges Faced

Efficacy and Safety of Edoxaban in Patients With AF and HF

Remote Patient Management:

Mitral Valve Disease.

Pseudobulbar Affect or Psychiatric Condition?

Using Heart Rate as a Biomarker in Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Case #1 Case #1 (cont) Case #1 (cont)

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Treatment-Resistant Schizophrenia

Case 1 Presentation Case 1 (cont) Assessment and Recommendations.

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

Reexamining the Basics of HFpEF

Expert Perspectives on Postoperative Ileus

Managing HF in Primary Care

Iron Deficiency in Heart Failure

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Program Goals Background: Anticoagulation in Patients With VTE.

Hypovolemic Shock.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

The ABCs of Diagnosing Tardive Dyskinesia

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

The Research Question Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are associated with many adverse outcomes HF and AF share.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Binge Eating Disorder.

Evaluating Success of Current Treatments for HCM

Uptitration of Medications in HF: Start Low but Aim High and Stay High

HF Definition. Why and How Should We Be Treating Patients With Heart Failure With Preserved Ejection Fraction?

Tardive Dyskinesia 101.

Merging the Art and Science of Managing nOH in Clinical Practice

Managing HF in Primary Care

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Understanding and Reducing Diagnostic Error

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Diagnosing HFpEF: What Every Cardiologist Needs to Know

HFpEF: Incidence, Prevalence and Outcomes

HFpEF: Why Is It So Difficult to Diagnose?

Challenges of the HFpEF Diagnosis

Heart Failure Definition

Similar Signs and Symptoms to HFrEF

Objective Evidence for Defining HFpEF

Confusion With the Diagnosis of HFpEF

Diagnostic Barriers for GPs in Diagnosing HF

Diagnosing HFpEF: Referral to the Cardiologist

Use of Stress Echocardiography and Right Heart Cath to Diagnose HFpEF

Consider Underlying Etiology in HFpEF

AF and HFpEF: Vicious Twins -- Diagnosis

AF and HFpEF: Vicious Twins -- Treatment

Assessment of BNP in AF and HFpEF Trials

H2FPEF Scoring

HFpEF: Low vs High BNP

Pathophysiology and Shared Mechanisms of HFpEF and AF

Ways to Improve the Process for Earlier Diagnosis of HFpEF

Conclusions: Take-Home Messages

Abbreviations

Abbreviations (cont)